Therapeutics News and Research

RSS

FORMA Therapeutics closes Series B financing to a total of $25.5 million

FORMA Therapeutics today announced that it has closed on a Series B financing that raised a total of $25.5 million. The round was led by new investor Lilly Ventures, with participation from existing investors Novartis Option Fund and Bio*One Capital of Singapore.

1 Dec 2009

TAP and pharma company team up to design Sonata, a unique system to speed drug development

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is delighted to announce that its Advanced Projects Group has partnered with a leading pharma company to successfully design and deliver Sonata™, a unique system for automated culturing and processing of cell lines in shake flasks.

1 Dec 2009

Aegis Therapeutics signs License Agreement with Roche

Aegis Therapeutics LLC (Aegis) announced today that they have signed a License Agreement providing Roche access to Aegis' proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.

1 Dec 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Study provides new insight into the mechanism of bacterial invasion protein

Spoiled meat is one of the sources for Listeria infections leading to listeriosis. Pregnant women, newborns and immune compromised people are susceptible for a severe progression of this disease. Firstly, the pathogen breaches the intestinal barrier and thus enters the body. The key for further spreading is the invasion protein internalin B that is located on the bacterial surface.

30 Nov 2009

GE Healthcare concentrates on healthymagination to help patients live longer and healthier

Miniaturized ultrasound. Navigation during interventional procedures. Innovations in sound wave imaging. At RSNA 2009, GE Healthcare is finding better ways to see more. And using that information to do more.

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

27 Nov 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

27 Nov 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

In honor of World AIDS Day, The AIDS Institute (TAI), one of the nation's leading advocacy organizations for support of people with HIV/AIDS and their providers, joined Nobel Laureate Dr. Francoise Barre-Sinoussi, in calling for government leaders, patient advocates and the research community to expand therapeutic HIV vaccine research.

26 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

The FDA granted traditional approval for INTELENCE® (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). INTELENCE is the only NNRTI specifically indicated for use in treatment-experienced adults who are experiencing virologic failure with HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents.

25 Nov 2009

Seven-day event focuses on nuclear medicine, molecular imaging, nanomedicine and clinical trials

SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.

25 Nov 2009

Tennessee Biotechnology Association to host workshop on biotechnology industry

The Tennessee Biotechnology Association and its Graduate Alliance are jointly hosting an afternoon of biotech, business, and law on December 7th, 2009. This event will be held at Belmont University with a reception at 5pm sponsored by i3 Research.

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

CHMP positive opinion for marketing ELONVA in Europe

PROLOR Biotech, Inc., today noted the positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing approval in Europe for ELONVA(R), a long-acting CTP-modified version of the fertility hormone FSH from Merck & Co. Merck and PROLOR are both licensees of the CTP technology from Washington University in St. Louis.

25 Nov 2009

Faulty enzyme may contribute to malignant brain tumour formation

Around 70 per cent of people with a type of brain tumour - called a low-grade glioma - have a faulty version of an enzyme called IDH1. The mutation is also found in a significant proportion of patients with acute myeloid leukaemia.

25 Nov 2009

Therapeutics News and Research

FORMA Therapeutics closes Series B financing to a total of $25.5 million

TAP and pharma company team up to design Sonata, a unique system to speed drug development

Aegis Therapeutics signs License Agreement with Roche

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Allos Therapeutics granted U.S. patent for FOLOTYN

ALS research collaboration receives philanthropic funding

Study provides new insight into the mechanism of bacterial invasion protein

GE Healthcare concentrates on healthymagination to help patients live longer and healthier

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Seven-day event focuses on nuclear medicine, molecular imaging, nanomedicine and clinical trials

Tennessee Biotechnology Association to host workshop on biotechnology industry

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

CHMP positive opinion for marketing ELONVA in Europe

Faulty enzyme may contribute to malignant brain tumour formation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News